+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Heart Failure (HF) - Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4985430
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 247 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • AstraZeneca
  • Boehringer Ingelheim
  • Cytokinetics
  • Merck Sharp & Dohme Corp
  • Quantum Genomics
  • MORE

The ‘Heart Failure (HF) - Market Insights, Epidemiology, and Market Forecast - 2028’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of HF in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Heart Failure (HF) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Heart Failure (HF)- Disease Understanding and Treatment Algorithm

Heart Failure (HF) is a chronic condition in which the heart muscle is incapable of pumping enough blood to meet the body's requirements for blood and oxygen. Few people face both problems simultaneously. Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. HF is triggered by structural and functional limitations in the myocardium resulting in damage to ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering the left ventricular myocardial utility along with the dysfunction of the pericardium, endocardium, heart valves or large vessels alone or in combination, ischemic heart disease, and diabetes. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart.

The four stages of HF are Stage A (pre-HF), Stage B (pre-HF but slightly closer to the worse phase of the disease), Stage C (Patients have been diagnosed with HF and is simultaneously dealing with the symptoms), Stage D and reduced E (HF have progressive symptoms that are difficult or slightly unable to get cured with treatment).

The initially caused symptoms of HF are shortness of breath and fatigue (tiredness), and the right-side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.  The assessment for HF is achieved using numerous parameters, like physical testing of the patient to know the occurrence of clinical symptoms of the HF, various blood tests, which includes complete blood count, urine analysis, serum creatinine, glucose, lipid fasting profile, metabolic profiling for serum electrolytes which contains magnesium and calcium, blood urea nitrogen, liver tests, and thyroid hormone estimation. There is no single diagnostic test for the determination of the HF. If a person has signs and symptoms of HF, then the physician recommends one or more tests that will be completed through a cardiologist.

The Heart Failure (HF) market report gives a thorough understanding of HF by including details such as disease introduction, types of HF, causes of HF, symptoms, pathophysiology, pathology, risk factors, diagnosis, diagnostic biomarkers, and differential diagnosis.

Heart Failure (HF) Epidemiology

According to the Centers for Disease Control and Prevention (CDC), about 5.7 million adults in the United States have heart failure. HF usually happens when the heart is unable to pump enough blood and oxygen to support other organs in the body. HF is a serious condition, but it does not mean that the heart has stopped beating. About half of people who develop heart failure die within 5 years of diagnosis.

According to the American Heart Association News, the number of people diagnosed with HF is increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with HF, according to the American Heart Association’s 2017 Heart Disease and Stroke Statistics Update (link opens in new window). The number of adults living with heart failure increased from about 5.7 million (2009-2012) to about 6.5 million (2011-2014). Data are based on National Health and Nutrition Examination Survey, which is taken in stages over multiple years.

According to the publisher, the total prevalent cases of HF in the 7MM was found to be 12,026,384 in 2017. The prevalent cases of HF in the 7MM are expected to increase during the study period of 2017-2028. Also, in 7MM the highest number of prevalent cases were observed in the US with 6,192,189 cases in 2017.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of HF in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017-2028 for the following aspects:

The disease epidemiology covered in the report is segmented by:

  • Prevalent Population of Heart Failure
  • Diagnosed Prevalent Population of Heart Failure
  • Gender-specific diagnosed prevalent cases of Heart Failure
  • Age-specific diagnosed prevalent cases of Heart Failure
  • NYHA class-specific diagnosed prevalent cases in the United State
  • Diagnosed prevalent cases of Heart Failure with Ejection Fraction
  • Diagnosed Prevalent cases of Heart Failure

A study conducted by Jackson et al. (2018) in the United States, HF affects approximately 6.5 million adults, and lifetime risk of HF is estimated to be 1 in 5 at 40 years of age. The incidence of HF increases with age, and HF prevalence in the aging US population is projected to increase by 46% between 2012 and 2030. Among hospitalizations for primary HF, the most common comorbid diagnoses were hypertension (72%), IHD (56%), diabetes mellitus (48%), chronic kidney disease (47%), and AF (43%). Among deaths with comorbid HF, the most common underlying causes were IHD (44%), hypertension (21%), and chronic obstructive pulmonary disease (21%).

As per the National Health Services (NHS), researchers compared the number of heart failure cases in the UK from 2002 to 2014. It was found that new cases of heart failure increased by 12% from 2002 to 2014. Instead, it was observed at how differences in socioeconomic status affected the number of heart failure cases in the UK. Out of the sample, 93,074 people were diagnosed with heart failure: 45,647 women and 47,427 men.

Heart Failure (HF) Drug Chapters

This segment of the Heart Failure (HF) report encloses the detailed analysis of the drugs that are expected to be launched in other regions. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of HF and awareness of the disease. The overall dynamics of the HF market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme Corp, and others will significantly increase the market during the forecast period (2019-2028).

Heart Failure (HF) Market Outlook

HF is generally defined as complex clinical syndrome categorized by distinct symptoms and signs which is caused by structural and functional cardiac aberrations. However, at present, the common term for describing heart failure is based on left ventricular ejection fraction. Also, HF with normal LVEF (= 50%) is known as HFpEF and HF with decreased LVEF (< 40%) as HFrEF. HF with a middle range of 40-49% is known as heart failure with mid-range ejection fraction (HFmrEF). But as of recent guidelines HFmrEF is considered as a separate unit, but the epidemiology, treatment, pathophysiology, and prognosis of HFmrEF are quite unclear.

Currently, the treatment of HF is dependent on angiotensin-converting enzyme inhibitor, angiotensin receptor II blocker, beta-blockers, and diuretics. Additionally, other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, among others are used for the treatment of patients affected by heart failure. Entresto and Corlanor are recently approved therapies for patients of heart failure. Entresto (sacubitril/valsartan) is a first-in-class angiotensin receptor/neprilysin inhibitor approved and marketed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Corlanor (ivabradine) comes under the brand name Corlanor, which is a new heart rate lowering medicine used as the symptomatic treatment in the case of stable angina pectoralis and chronic heart failure.

This segment gives a thorough detail of market trend of each therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market for HF in the 7MM was found to be approximately 5,148.32 Million in 2017.

Heart Failure (HF) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of HF market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as empagliflozin (Boehringer Ingelheim/Eli Lilly and Company), vericiguat (Merck Sharp & Dohme Corp./Bayer), AZD4831 (AstraZeneca), dapagliflozin/farxiga (AstraZeneca), omecamtiv mecarbil (Amgen/Cytokinetics/Servier), RT-110 (Renova Therapeutics), RT-400 (Renova Therapeutics),  BMS-986231 (Bristol-Myers Squibb), Elamipretide (Stealth BioTherapeutics), Firibastat (Quantum Genomics), Macitentan (Actelion Pharmaceuticals), in the HF market by 2028.

Heart Failure (HF) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Heart Failure (HF) Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Heart Failure (HF) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving the HF market
  • Organize sales and marketing efforts by identifying the best opportunities for the HF market
  • To understand the future market competition in the HF market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • AstraZeneca
  • Boehringer Ingelheim
  • Cytokinetics
  • Merck Sharp & Dohme Corp
  • Quantum Genomics
  • MORE

1. Key Insights

2. Heart Failure (HF) Market Overview at a Glance
2.1. Market Share (%) Distribution of Heart Failure (HF) in 2017
2.2. Market Share (%) Distribution of Heart Failure (HF) in 2028

3. Disease Background and Overview: Heart Failure (HF)
3.1. Introduction
3.2. Causes of HF
3.3. Signs and Symptoms
3.4. Stages of HF
3.4.1. Stage A
3.4.2. Stage B
3.4.3. Stage C
3.4.4. Stage D and reduced E
3.5. Classification of HF
3.6. Common pathophysiologic mechanisms in HF
3.6.1. Structural Heart Disease and Mechanical Stress: Pressure/Volume Overload
3.6.2. Neurohormonal Dysregulation
3.6.3. Ischemic Injury: Replacement Fibrosis and Hibernating Myocardium
3.6.4. Abnormal Intracellular Calcium Handling
3.6.5. Genetic Mutations
3.7. Biomarkers for the HF
3.7.1. Characteristics of Other Biomarkers for HF
3.8. Diagnosis
3.8.1. Medical and Family Histories
3.9. Diagnostic Tests
3.9.1. EKG (Electrocardiogram)
3.9.2. Chest x-ray
3.9.3. Echocardiography
3.9.4. Doppler Ultrasound
3.9.5. Holter Monitor
3.9.6. Nuclear Heart Scan
3.9.7. Cardiac Catheterization
3.9.8. Coronary Angiography
3.9.9. Stress Test
3.9.10. Cardiac MRI
3.10. Differential Diagnosis

4. Diagnostic Guidelines
4.1. American College of Cardiology (ACC), American Heart Association (AHA), and HF Society of America (HFSA) (2017)
4.2. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF
4.2.1. Essential initial investigations: natriuretic peptides, electrocardiogram and echocardiography
4.2.2. Diagnosis of HF with a preserved ejection fraction
4.2.3. Cardiac imaging and other diagnostic tests
4.3. Diagnostic Algorithm

5. Recognized Establishments

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Countries Prevalent Patient Population of Heart Failure
6.3. 7MM Countries Diagnosed Prevalent Patient Population of Heart Failure

7. Country Wise-Epidemiology of HF
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Prevalent Population of Heart Failure in the United States
7.1.3. Diagnosed Prevalent Population of Heart Failure in the United States
7.1.4. Gender-specific diagnosed prevalent cases of Heart Failure in the United States
7.1.5. Age-specific diagnosed prevalent cases of Heart Failure in the United States
7.1.6. NYHA class-specific diagnosed prevalent cases in the United States
7.1.7. Diagnosed prevalent cases of Heart Failure with Ejection Fraction in the United States
7.1.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United States
7.2. EU5 Countries
7.3. Germany
7.3.1. Prevalent Population of Heart Failure in Germany
7.3.2. Diagnosed Prevalent Population of Heart Failure in Germany
7.3.3. Gender-specific diagnosed prevalent cases of Heart Failure in Germany
7.3.4. Age-specific diagnosed prevalent cases of Heart Failure in Germany
7.3.5. NYHA class-specific diagnosed prevalent cases in Germany
7.3.6. Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Germany
7.3.7. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Germany
7.4. France
7.4.1. Assumptions and Rationale
7.4.2. Prevalent Population of Heart Failure in France
7.4.3. Diagnosed Prevalent Population of Heart Failure in France
7.4.4. Gender-specific diagnosed prevalent cases of Heart Failure in France
7.4.5. Age-specific diagnosed prevalent cases of Heart Failure in France
7.4.6. NYHA class-specific diagnosed prevalent cases in France
7.4.7. Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in France
7.4.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in France
7.5. Italy
7.5.1. Assumptions and Rationale
7.5.2. Prevalent Population of Heart Failure in Italy
7.5.3. Diagnosed Prevalent Population of Heart Failure in Italy
7.5.4. Gender-specific diagnosed prevalent cases of Heart Failure in Italy
7.5.5. Age-specific diagnosed prevalent cases of Heart Failure in Italy
7.5.6. NYHA class-specific diagnosed prevalent cases in Italy
7.5.7. Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Italy
7.5.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Italy
7.6. Spain
7.6.1. Assumptions and Rationale
7.6.2. Prevalent Population of Heart Failure in Spain
7.6.3. Diagnosed Prevalent Population of Heart Failure in Spain
7.6.4. Gender-specific diagnosed prevalent cases of Heart Failure in Spain
7.6.5. Age-specific diagnosed prevalent cases of Heart Failure in Spain
7.6.6. NYHA class-specific diagnosed prevalent cases in Spain
7.6.7. Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Spain
7.6.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Spain
7.7. United Kingdom
7.7.1. Assumptions and Rationale
7.7.2. Prevalent Population of Heart Failure in the United Kingdom
7.7.3. Diagnosed Prevalent Population of Heart Failure in the United Kingdom
7.7.4. Gender-specific diagnosed prevalent cases of Heart Failure in the United Kingdom
7.7.5. Age-specific diagnosed prevalent cases of Heart Failure in the United Kingdom
7.7.6. NYHA class-specific diagnosed prevalent cases in the United Kingdom
7.7.7. Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in the United Kingdom
7.7.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United Kingdom
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Prevalent Population of Heart Failure in Japan
7.8.3. Diagnosed Prevalent Population of Heart Failure in Japan
7.8.4. Gender-specific diagnosed prevalent cases of Heart Failure in Japan
7.8.5. Age-specific diagnosed prevalent cases of Heart Failure in Japan
7.8.6. NYHA class-specific diagnosed prevalent cases in Japan
7.8.7. Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Japan
7.8.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Japan

8. Treatment
8.1. Angiotensin-converting enzyme (ACE) inhibitors
8.2. Angiotensin II receptor blockers (ARBs)
8.3. Mineralocorticoid receptor antagonists (MRAs)
8.4. If-Channel Inhibitor
8.5. Beta-blockers
8.6. Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
8.7. Diuretics
8.8. Digoxin (Lanoxin)
8.9. Hydralazine and isosorbide dinitrate
8.10. Statins
8.11. Anticoagulants
8.12. Dual Antiplatelet Therapy (DAPT)
8.13. Unique characteristics of heart failure treatment in Japan
8.13.1. Carperitide
8.13.2. Nicorandil
8.13.3. Landiolol
8.13.4. Tolvaptan
8.13.5. Pimobendan
8.13.6. Waon therapy
8.14. Non-pharmacological intervention and lifestyle modification

9. Treatment Guidelines of Heart Failure

10. European Society of Cardiology (ESC) Guidelines: 2016
10.1. Pharmacological treatment of heart failure with reduced ejection fraction
10.1.1. Objectives in the management of heart failure
10.2. Treatments recommended in all symptomatic patients with heart failure with a reduced ejection fraction
10.2.1. Angiotensin-converting enzyme inhibitors
10.2.2. Beta-blockers
10.2.3. Mineralocorticoid/aldosterone receptor antagonists
10.3. Other treatments recommended in selected symptomatic patients with heart failure with a reduced ejection fraction
10.3.1. Diuretics
10.3.2. Angiotensin receptor neprilysin inhibitor
10.3.3. If-channel inhibitor
10.3.4. Angiotensin II type I receptor blockers
10.3.5. Combination of hydralazine and isosorbide dinitrate
10.4. Other treatments with less certain benefits in symptomatic patients with heart failure with a reduced ejection fraction
10.4.1. Digoxin and other digital
10.4.2. n-3 polyunsaturated fatty acids
10.5. Treatments not recommended (unproven benefit) in symptomatic patients with heart failure with a reduced ejection fraction
10.5.1. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (‘statins’)
10.5.2. Oral anticoagulants and antiplatelet therapy
10.5.3. Renin-inhibitors
10.6. Treatments not recommended (believed to cause harm) in symptomatic patients with heart failure with a reduced ejection fraction
10.6.1. Calcium-channel blockers

11. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version

12. Unmet Needs

13. Marketed Drugs
13.1. Marketed Drugs Key-cross Competition
13.2. Entresto (sacubitril and valsartan): Novartis
13.2.1. Drug Description
13.2.2. Regulatory Milestones
13.2.3. Other Development Activities
13.2.4. Safety and Efficacy
13.2.5. Current pipeline activities
13.2.6. Product Profile
13.3. Corlanor (ivabradine): Amgen
13.3.1. Drug Description
13.3.2. Regulatory Milestones
13.3.3. Other Development Activities
13.3.4. Safety and Efficacy
13.3.5. Product Profile

14. Emerging Drugs
14.1. Key Cross Competition
14.2. Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Development
14.2.4. Product Profile
14.3. Vericiguat (BAY1021189): Merck Sharp & Dohme Corp/Bayer
14.3.1. Product Description
14.3.2. Other Developmental Activities
14.3.3. Clinical Development
14.3.4. Safety and Efficacy
14.3.5. Product Profile
14.4. AZD4831: AstraZeneca
14.4.1. Product Description
14.4.2. Clinical Development
14.4.3. Safety and Efficacy
14.4.4. Product Profile
14.5. Dapagliflozin: AstraZeneca
14.5.1. Product Description
14.5.2. Other Developmental Activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.5.5. Product Profile
14.6. Omecamtiv mecarbil: Amgen/Cytokinetics/Servier
14.6.1. Product Description
14.6.2. Other Developmental Activities
14.6.3. Clinical Development
14.6.4. Safety and Efficacy
14.6.5. Product Profile
14.7. RT-100 (Ad5.hAC6): Renova Therapeutics
14.7.1. Product Description
14.7.2. Other Developmental Activities
14.7.3. Clinical Development
14.7.4. Safety and Efficacy
14.7.5. Product Profile
14.8. RT-400 (JNJ-39588146): Renova Therapeutics
14.8.1. Product Description
14.8.2. Other Developmental Activities
14.8.3. Clinical Development
14.8.4. Safety and Efficacy
14.8.5. Product Profile
14.9. BMS-986231 (Nitroxyl Donor): Bristol-Myers Squibb
14.9.1. Product Description
14.9.2. Other Developmental Activities
14.9.3. Clinical Development
14.9.4. Safety and Efficacy
14.9.5. Product Profile
14.10. Elamipretide (MT-131): Stealth BioTherapeutics
14.10.1. Product Description
14.10.2. Clinical Development
14.10.3. Safety and Efficacy
14.10.4. Product Profile
14.11. Firibastat: Quantum Genomics
14.11.1. Product Description
14.11.2. Other Developmental Activities
14.11.3. Clinical Development
14.11.4. Product Profile
14.12. Macitentan: Actelion Pharmaceuticals
14.12.1. Product Description
14.12.2. Other Developmental Activities
14.12.3. Clinical Development
14.12.4. Product Profile

15. Heart Failure (HF): 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of Heart Failure in the 7MM Countries

16. Market Outlook in the 7MM
16.1. Expected Launch Date of Pipeline Products
16.2. United States
16.2.1. Total Market size of HF
16.2.2. Market Size by Therapies
16.3. Germany
16.3.1. Total Market size of Heart Failure
16.3.2. Market Size by Therapies
16.4. France
16.4.1. Total Market size of Heart Failure
16.4.2. Market Size of Heart Failure by Therapies
16.5. Italy
16.5.1. Total Market Size of Heart Failure
16.5.2. Market Size of Heart Failure by Therapies
16.6. Spain
16.6.1. Total Market Size of Heart Failure
16.6.2. Market Size of Heart Failure by Therapies
16.7. United Kingdom
16.7.1. Total Market Size of Heart Failure
16.7.2. Market Size by Therapies
16.8. Japan
16.8.1. Total Market Size of Heart Failure
16.8.2. Market Size by Therapies

17. Case Reports
17.1. A Case Report of Dilated Biventricular Heart Failure from Hyperthyroidism: A Rare Presentation
17.2. Clinical case: heart failure and ischemic heart disease
17.3. A Case of Left Ventricular Endoventricular Patch Plasty for Severe Heart Failure Induced by Ischemic Cardiomyopathy

18. Market Drivers

19. Market Barriers

20. Appendix
20.1. Report Methodology

21. Capabilities

22. Disclaimer

23. About the Publisher

List of Tables
Table 1: HF Classification based on the New York Heart Association
Table 2: HF Classification based on the New York Heart Association
Table 3: HF Classification based on the American College of Cardiology
Table 4: Shift along the Frank-Starling Curve and Its Causes
Table 5: Characteristics of Other Biomarkers for HF
Table 6: Different test for the estimation of the HF
Table 7: Recommendations for measuring biomarkers in HF
Table 8: Recommendations for managing blood pressure in HF
Table 9: Total Prevalent Population of Heart Failure in the 7MM Countries (2017-2028)
Table 10: Total Diagnosed Prevalent Population of Heart Failure in the 7MM Countries (2017-2028)
Table 11: Prevalent Population of Heart Failure in the United States (2017-2028)
Table 12: Diagnosed Prevalent Population of Heart Failure in the United States (2017-2028)
Table 13: Gender-specific diagnosed prevalent cases of Heart Failure in the United States (2017-2028)
Table 14: Age-specific diagnosed prevalent cases of Heart Failure in the United States (2017-2028)
Table 15: NYHA class-specific diagnosed prevalent cases in the United States (2017-2028)
Table 16: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in the United States (2017-2028)
Table 17: Diagnosed Prevalent cases of HF associated with comorbidities in the United States (2017-2028)
Table 18: Prevalent Population of Heart Failure in Germany (2017-2028)
Table 19: Diagnosed Prevalent Population of Heart Failure in Germany (2017-2028)
Table 20: Gender-specific diagnosed prevalent cases of Heart Failure in Germany (2017-2028)
Table 21: Age-specific diagnosed prevalent cases of Heart Failure in Germany (2017-2028)
Table 22: NYHA class-specific diagnosed prevalent cases in Germany (2017-2028)
Table 23: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Germany (2017-2028)
Table 24: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Germany (2017-2028)
Table 25: Prevalent Population of Heart Failure in France (2017-2028)
Table 26: Diagnosed Prevalent Population of Heart Failure in France (2017-2028)
Table 27: Gender-specific diagnosed prevalent cases of Heart Failure in France (2017-2028)
Table 28: Age-specific diagnosed prevalent cases of Heart Failure in France (2017-2028)
Table 29: NYHA class-specific diagnosed prevalent cases in France (2017-2028)
Table 30: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in France (2017-2028)
Table 31: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in France (2017-2028)
Table 32: Prevalent Population of Heart Failure in Italy (2017-2028)
Table 33: Diagnosed Prevalent Population of Heart Failure in Italy (2017-2028)
Table 34: Gender-specific diagnosed prevalent cases of Heart Failure in Italy (2017-2028)
Table 35: Age-specific diagnosed prevalent cases of Heart Failure in Italy (2017-2028)
Table 36: NYHA class-specific diagnosed prevalent cases in Italy (2017-2028)
Table 37: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Italy (2017-2028)
Table 38: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Italy (2017-2028)
Table 39: Prevalent Population of Heart Failure in Spain (2017-2028)
Table 40: Diagnosed Prevalent Population of Heart Failure in Spain (2017-2028)
Table 41: Gender-specific diagnosed prevalent cases of Heart Failure in Spain (2017-2028)
Table 42: Age-specific diagnosed prevalent cases of Heart Failure in Spain (2017-2028)
Table 43: NYHA class-specific diagnosed prevalent cases in Spain (2017-2028)
Table 44: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Spain (2017-2028)
Table 45: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Spain (2017-2028)
Table 46: Prevalent Population of Heart Failure in the United Kingdom (2017-2028)
Table 47: Diagnosed Prevalent Population of Heart Failure in the United Kingdom (2017-2028)
Table 48: Gender-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2017-2028)
Table 49: Age-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2017-2028)
Table 50: NYHA class-specific diagnosed prevalent cases in the United Kingdom (2017-2028)
Table 51: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in the United Kingdom (2017-2028)
Table 52: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United Kingdom (2017-2028)
Table 53: Prevalent Population of Heart Failure in Japan (2017-2028)
Table 54: Diagnosed Prevalent Population of Heart Failure in Japan (2017-2028)
Table 55: Gender-specific diagnosed prevalent cases of Heart Failure in Japan (2017-2028)
Table 56: Age-specific diagnosed prevalent cases of Heart Failure in Japan (2017-2028)
Table 57: NYHA class-specific diagnosed prevalent cases in Japan (2017-2028)
Table 58: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Japan (2017-2028)
Table 59: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Japan (2017-2028)
Table 60: Guidelines for the diagnosis of Heart Failure
Table 61: Recommendations and Levels of Evidence for Medications for HFrEF
Table 62: Comparison of Marketed Drugs
Table 63: Entresto (sacubitril and valsartan), Clinical Trial Description
Table 64: Comparison of Emerging Drugs
Table 65: Empagliflozin, Clinical Trial Description
Table 66: Vericiguat, Clinical Trial Description
Table 67: AZD4831, Clinical Trial Description
Table 68: Dapagliflozin, Clinical Trial Description
Table 69: Omecamtiv mecarbil, Clinical Trial Description
Table 70: RT-100, Clinical Trial Description
Table 71: RT-400, Clinical Trial Description
Table 72: BMS-986231, Clinical Trial Description
Table 73: Elamipretide, Clinical Trial Description
Table 74: Firibastat, Clinical Trial Description
Table 75: Macitentan, Clinical Trial Description
Table 76: 7 Major Market Size of HF in USD Million (2017-2028)
Table 77: United States Market Size of HF, USD Million (2017-2028)
Table 78: Market size of HF by therapies in the United States, in USD Million (2017-2028)
Table 79: Market Size of Heart Failure in Germany, in USD Million (2017-2028)
Table 80: Market size of HF by therapies in Germany, in USD Million (2017-2028)
Table 81: Market Size of Heart Failure in France, in USD Million (2017-2028)
Table 82: Market size of Heart Failure by therapies in France, in USD Million (2017-2028)
Table 83: Market Size of Heart Failure in Italy, in USD Million (2017-2028)
Table 84: Market size of Heart Failure by therapies in Italy, in USD Million (2017-2028)
Table 85: Market Size of Heart Failure in Spain, in USD Million (2017-2028)
Table 86: Market size of Heart Failure by therapies in Spain, in USD Million (2017-2028)
Table 87: Market Size of Heart Failure in the UK, in USD Million (2017-2028)
Table 88: Market size of Heart Failure by therapies in the UK, in USD Million (2017-2028)
Table 89: Market Size of Heart Failure in Japan, in USD Million (2017-2028)
Table 90: Market size of Heart Failure by therapies in Japan, in USD Million (2017-2028)

List of Figures
Figure 1: Different condition in HF
Figure 2: Causes of HF
Figure 3: Stages of HF
Figure 4: Common pathophysiologic mechanisms in HF
Figure 5: Common pathophysiologic mechanisms in HF
Figure 6: Total Prevalent Patient Population of HF in the 7MM Countries (2017-2028)
Figure 7: Total Diagnosed Prevalent Patient Population of Heart Failure in the 7MM Countries (2017-2028)
Figure 8: Prevalent Population of Heart Failure in the United States (2017-2028)
Figure 9: Diagnosed Prevalent Population of Heart Failure in the United States (2017-2028)
Figure 10: Gender-specific diagnosed prevalent cases of Heart Failure in the United States (2017-2028)
Figure 11: Age-specific diagnosed prevalent cases of Heart Failure in the United States (2017-2028)
Figure 12: NYHA class-specific diagnosed prevalent cases in the United States (2017-2028)
Figure 13: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in the United States (2017-2028)
Figure 14: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United States (2017-2028)
Figure 15: Prevalent Population of Heart Failure in Germany (2017-2028)
Figure 16: Diagnosed Prevalent Population of Heart Failure in Germany (2017-2028)
Figure 17: Gender-specific diagnosed prevalent cases of Heart Failure in Germany (2017-2028)
Figure 18: Age-specific diagnosed prevalent cases of Heart Failure in Germany (2017-2028)
Figure 19: NYHA class-specific diagnosed prevalent cases in Germany (2017-2028)
Figure 20: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Germany (2017-2028)
Figure 21: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Germany (2017-2028)
Figure 22: Prevalent Population of Heart Failure in France (2017-2028)
Figure 23: Diagnosed Prevalent Population of Heart Failure in France (2017-2028)
Figure 24: Gender-specific diagnosed prevalent cases of Heart Failure in France (2017-2028)
Figure 25: Age-specific diagnosed prevalent cases of Heart Failure in France (2017-2028)
Figure 26: NYHA class-specific diagnosed prevalent cases in France (2017-2028)
Figure 27: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in France (2017-2028)
Figure 28: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in France (2017-2028)
Figure 29: Prevalent Population of Heart Failure in Italy (2017-2028)
Figure 30: Diagnosed Prevalent Population of Heart Failure in Italy (2017-2028)
Figure 31: Gender-specific diagnosed prevalent cases of Heart Failure in Italy (2017-2028)
Figure 32: Age-specific diagnosed prevalent cases of Heart Failure in Italy (2017-2028)
Figure 33: NYHA class-specific diagnosed prevalent cases in Italy (2017-2028)
Figure 34: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Italy (2017-2028)
Figure 35: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Italy (2017-2028)
Figure 36: Prevalent Population of Heart Failure in Spain (2017-2028)
Figure 37: Diagnosed Prevalent Population of Heart Failure in Spain (2017-2028)
Figure 38: Gender-specific diagnosed prevalent cases of Heart Failure in Spain (2017-2028)
Figure 39: Age-specific diagnosed prevalent cases of Heart Failure in Spain (2017-2028)
Figure 40: NYHA class-specific diagnosed prevalent cases in Spain (2017-2028)
Figure 41: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Spain (2017-2028)
Figure 42: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Spain (2017-2028)
Figure 43: Prevalent Population of Heart Failure in the United Kingdom (2017-2028)
Figure 44: Diagnosed Prevalent Population of Heart Failure in the United Kingdom (2017-2028)
Figure 45: Gender-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2017-2028)
Figure 46: Age-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2017-2028)
Figure 47: NYHA class-specific diagnosed prevalent cases in the United Kingdom (2017-2028)
Figure 48: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Spain (2017-2028)
Figure 49: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United Kingdom (2017-2028)
Figure 50: Prevalent Population of Heart Failure in Japan (2017-2028)
Figure 51: Diagnosed Prevalent Population of Heart Failure in Japan (2017-2028)
Figure 52: Gender-specific diagnosed prevalent cases of Heart Failure in Japan (2017-2028)
Figure 53: Age-specific diagnosed prevalent cases of Heart Failure in Japan (2017-2028)
Figure 54: NYHA class-specific diagnosed prevalent cases Japan (2017-2028)
Figure 55: Diagnosed Prevalent cases of Heart Failure with Ejection Fraction in Japan (2017-2028)
Figure 56: Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Japan (2017-2028)
Figure 57: Different Classes of Drug
Figure 58: Evidence-based doses of disease-modifying drugs in key randomized trials in heart failure with reduced ejection fraction (or after myocardial infarction)
Figure 59: 7 Major Market Size of Heart Failure in USD Million (2017-2028)
Figure 60: Market Size of HF in the United States, USD Millions (2017-2028)
Figure 61: Market size of HF by therapies in the US, in USD Million (2017-2028)
Figure 62: Market Size of Heart Failure in Germany, USD Million (2017-2028)
Figure 63: Market Size of HF by therapies, in Germany, in USD Million (2017-2028)
Figure 64: Market Size of Heart Failure in France, USD Million (2017-2028)
Figure 65: Market Size of Heart Failure by therapies, in France, in USD Million (2017-2028)
Figure 66: Market Size of Heart Failure in Italy, USD Million (2017-2028)
Figure 67: Market Size of Heart Failure by therapies, in Italy, in USD Million (2017-2028)
Figure 68: Market Size of Heart Failure in Spain, USD Million (2017-2028)
Figure 69: Market Size of Heart Failure by therapies in Spain, in USD Million (2017-2028)
Figure 70: Market Size of Heart Failure in the UK, USD Million (2017-2028)
Figure 71: Market Size of Heart Failure by therapies in the UK, in USD Million (2017-2028)
Figure 72: Market Size of Heart Failure in Japan, USD Million (2017-2028)
Figure 73: Market Size of Heart Failure by therapies in Japan, in USD Million (2017-2028)

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actelion Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cytokinetics
  • Eli Lilly and Company
  • Merck Sharp & Dohme Corp
  • Novartis
  • Quantum Genomics
  • Renova Therapeutics
  • Servier
  • Stealth BioTherapeutics
Note: Product cover images may vary from those shown
Adroll
adroll